NCT03289039: Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

NCT03289039
Breast Cancer Type: HER2+
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have both ER+ & HER2+ tumors
Exclusions: Participants with symptomatic or progressive brain metastases, or requiring steroids to control symptoms of brain metastases
https://ClinicalTrials.gov/show/NCT03289039

Comments are closed.

Up ↑